Alyeska Investment Group L.P. purchased a new position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 140,720 shares of the biopharmaceutical company’s stock, valued at approximately $892,000. Alyeska Investment Group L.P. owned about 0.16% of Inovio Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Allianz Asset Management GmbH lifted its stake in shares of Inovio Pharmaceuticals by 12.4% in the 3rd quarter. Allianz Asset Management GmbH now owns 222,768 shares of the biopharmaceutical company’s stock valued at $1,412,000 after purchasing an additional 24,652 shares in the last quarter. Engineers Gate Manager LP acquired a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at about $117,000. OxFORD Asset Management LLP lifted its stake in shares of Inovio Pharmaceuticals by 410.3% in the 3rd quarter. OxFORD Asset Management LLP now owns 126,404 shares of the biopharmaceutical company’s stock valued at $799,000 after purchasing an additional 101,633 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of Inovio Pharmaceuticals by 16.1% in the 3rd quarter. Wells Fargo & Company MN now owns 103,680 shares of the biopharmaceutical company’s stock valued at $657,000 after purchasing an additional 14,342 shares in the last quarter. Finally, Virginia Retirement Systems ET AL acquired a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at about $101,000. 32.27% of the stock is currently owned by institutional investors and hedge funds.

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) opened at $4.28 on Friday. Inovio Pharmaceuticals, Inc. has a twelve month low of $4.20 and a twelve month high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The firm had revenue of $2.60 million during the quarter, compared to the consensus estimate of $10.27 million. During the same quarter last year, the firm posted ($0.28) earnings per share. Inovio Pharmaceuticals’s revenue was down 79.2% compared to the same quarter last year. sell-side analysts anticipate that Inovio Pharmaceuticals, Inc. will post -1.12 EPS for the current year.

Several research firms have recently weighed in on INO. BidaskClub lowered Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, October 27th. Citigroup began coverage on Inovio Pharmaceuticals in a report on Wednesday, September 6th. They set a “buy” rating and a $10.00 target price on the stock. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 28th. Zacks Investment Research downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Finally, Maxim Group reiterated a “buy” rating and set a $12.00 target price on shares of Inovio Pharmaceuticals in a report on Tuesday, September 12th. Three analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. Inovio Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $19.16.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/alyeska-investment-group-l-p-takes-892000-position-in-inovio-pharmaceuticals-inc-ino/1764944.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals, Inc. (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.